Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Ergebnis 24 von 96
European journal of clinical investigation, 2017-07, Vol.47 (7), p.531-539
2017

Details

Autor(en) / Beteiligte
Titel
Treatment of severe alcoholic hepatitis: past, present and future
Ist Teil von
  • European journal of clinical investigation, 2017-07, Vol.47 (7), p.531-539
Ort / Verlag
England: Blackwell Publishing Ltd
Erscheinungsjahr
2017
Link zum Volltext
Quelle
MEDLINE
Beschreibungen/Notizen
  • Alcoholic hepatitis (AH) manifests as a clinical syndrome characterized by recent jaundice and liver function deterioration in an actively drinking patient. The principal cause of AH is alcoholic steatohepatitis (ASH) defined histologically by the coexistence of steatosis, hepatocyte ballooning and satellitosis. While nonsevere AH usually responds to alcohol abstinence, severe AH, identified by Maddrey scoring ≥ 32, has a bad prognosis and is traditionally treated by a 28‐day course of prednisone therapy. A recent trial, which showed no improvement of long‐term survival but significant reduced mortality after 28 days of corticoid therapy compared to placebo, opens a debate on its efficacy. N‐acetyl‐cysteine supplementation combined with steroid therapy is also able to reduce the 28‐day mortality compared to steroid alone. While guidelines recommend high‐calorie intake and protein supplementation in decompensated liver diseases, intensive enteral nutrition together with corticoid treatment does not reduce mortality compared to corticoid alone in a recent study with ASH patients. Stimulation of liver regeneration through interleukin‐22, granulocyte colony‐stimulating factor or farnesoid X receptor agonists, inhibition of apoptosis, early liver transplantation and modulation of gut microbiota through antibiotic or faecal transplantation approaches constitute new therapeutic perspectives that are investigated in current clinical trials. Inhibition of oxidative stress, modulation of gut fungal populations and stimulation of progenitor cell proliferation and pro‐regenerative inflammatory pathways constitute prospects for future human trials. For long‐term survival, strategies for persistent alcohol abstinence remain the key of success, opening another large research field.
Sprache
Englisch
Identifikatoren
ISSN: 0014-2972
eISSN: 1365-2362
DOI: 10.1111/eci.12767
Titel-ID: cdi_proquest_miscellaneous_1900125102

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX